Imran Nizamuddin

Hematology/Oncology fellow at WashU @WUHemeOncFellow via @NU_IntMed | @umkcmedschool grad | Tweets ≠ medical advice

[WashU Medicine Hematology-Oncology Fellowship @WashUHemOncFell]

Congratulations to one our outstanding @WashUHemOncFell Emily Podany @podanymd on the publication of her article "Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer" in @JAMANetworkOpen
@WashUOncology

https://t.co/0hooLKp1BY

[Imran Nizamuddin @INizMD]

Grateful to my mentors
@nehamehtashahmd
and Nancy Bartlett as well as ASH
@ASH_hematology
for giving me the opportunity to present our work! #ASH2024

[David Russler-Germain, MD/PhD @dgermain21]

Woot woot! @INizMD @NehaMehtaShahMD presenting their IIS examining acalabrutinib + durvalumab in relapsed CNS lymphoma.

@SitemanCenter @WashUOncology @WashUHemOncFell

[Vincent Rajkumar @VincentRK]

AQUILA trial for high risk smoldering myeloma published in @NEJM today.
@thanosdimop

Personally for me, it is a huge milestone along 25 years of work that started in 1998. #ASH24 #ASH24VR

This story below may help those interested in a clinical trialist career.
1/

[Imran Nizamuddin @INizMD]

@JOEBENNETTMD @dgermain21 @NehaMehtaShahMD @SitemanCenter @WashUOncology @WashUHemOncFell Thanks, Joe! Sad we didn't get a chance to meet up this weekend!

[Eddie Cliff @Eddie_Cliff]

Impressive results for CD19 directed ADC loncastuximab tesirine in follicular lymphoma - why was it not developed in FL sooner?!

Now published in @TheLancetHaem https://t.co/dx1rFSxG1M

(almost all patients CAR T naive)

#ASH24 #lymsm

[Eddie Cliff @Eddie_Cliff]

ENRICH: ibrutinib+R vs BR or RCHOP

IR better PFS than RCHOP but *not* better than BR

Reasonable to consider BTKi first line in patient who prefers to avoid benda but I suspect unlikely to be cost effective given continuous therapy

#ASH24 #lymsm

[David Russler-Germain, MD/PhD @dgermain21]

Two big lymphoma late breaking abstracts @ASH_hematology #ASH2024

Tafa-R-Len beats R-Len in rel/ref FL

https://t.co/9Lx62lgH6g

AutoSCT not beneficial in 1L MCL if in CR/uMRD (most patients with modern induction)

https://t.co/4WiqaWx4lK

[Ajay Major, MD, MBA @majorajay]

Huge SCNSL cohort @JuanAlderuccio @CwynKate #ASH24:
- 1173 pts, 45% de novo
- mPFS 11 mo, mOS 21 mo (better if de novo: 13 & 47 mo)
- de novo: 28% relapse post ASCT
- R/R: 1-yr relapse 21% post ASCT, 56% post CAR
Better OS w/ ASCT consolidation in de novo & relapsed dx. #lymsm

[SWOG Cancer Research Network @SWOG]

Nivo+AVD led to longer progression-free survival than standard BV+AVD in adolescents & adults with stage III or IV advanced-stage classic Hodgkin lymphoma & had a better side-effect profile. Results of @SWOG @COGorg S1826 in @NEJM. @DrJFriedberg @theNCI https://t.co/9vaTJVP3fg

[Ajay Major, MD, MBA @majorajay]

My favorite trial as a fellow: the MRD2STOP discontinuation trial by @bdermanmd is now published!
Short thread of findings, including patient-reported outcomes (many thanks to the research team for the opportunity to integrate & analyze these PROs). #mmsm
https://t.co/jv5S6YDA8o

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

👏👏 Kudos to Dr Mitchell Smith and @SitemanCenter Dr Brad Kahl on this large prospective, @eaonc randomized study in #MantleCellLymphoma. An important contribution to the field!

[Othman Al-Sawaf @Othman_Al_Sawaf]

Check out our latest paper in @JCO_ASCO on surrogacy of endpoints in 1L #CLL trials!

Led by @Sim_Florian, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇

https://t.co/gHX3zOWeII

[Mehdi Hamadani, MD @MediHumdani]

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results | Journal of Clinical Oncology https://t.co/EWufWkWFdm very important analysis!!! #lymsm

[Syed Ali Abutalib @syed_abutalibmd]

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) | Journal of Clinical Oncology https://t.co/G7DlmFXkPS

[Megan Melody MD, MS @heMEGirl_MD]

Had the opportunity to attempt to “demystify” the fellowship application process with @docbraunstein and @chadinabhan on the Healthcare Unfiltered podcast. A great listen for those applying/planning to apply fellowship!

https://t.co/A8MC2U3iKA

[Oncology Brothers @OncBrothers]

Vorasidenib now @FDAOncology approved based off Ph3 #INDIGO for residual/recurrent Gr 2 Astrocytoma/Oligodendroglioma w/ IDH1/2 mutation!

-mPFS, 27.7mos vs. 11.1mos (HR: 0.39)
- Time to next intervention was significantly improved
- Gr ≥ 3 AEs 22.8%

#OncTwitter #NeuroOnc

[Nitin Jain @NitinJainMD]

👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journal Lancet today!! @TheLancet
@wwierda @MDAndersonNews @DrHKantarjian

Chronic lymphocytic leukaemia - The Lancet https://t.co/9BhwN0Yffp

[Benlazar S M A @smbenlazar]

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial - Suo - 2024 - Hematological Oncology - Wiley Online Library https://t.co/bFMz2cmknu #leusm #AML

[Dr. Glaucomflecken @DGlaucomflecken]

The most dangerous grift in ophthalmology right now is “glasses are harmful.” People that claim diet, exercise, and a 10 part instructional webinar can help you live spectacle free! No. Stop it.

It’s not a big deal for most adults. They will lose some money before realizing that no amount of exercise and bull testicle consumption will fix their presbyopia.

But those same adults have kids. If young kids don’t get the glasses they need, their brains won’t develop normal vision. I’m talking permanent vision loss. I have seen it happen. It’s awful and entirely preventable.

[Mark Lewis, MD, FASCO @marklewismd]

WHY I (ALMOST) NEVER BOLUS 5-FLUOROURACIL

I've been pondering this thread for a while but it's become more urgent in light of another looming chemo shortage <deep sigh>, this time with an imminent dearth of THE foundational drug of GI oncology: 5-fluorouracil, or 5-FU